Equity strategies

Carmignac Portfolio Grande Europe

Luxembourg SICAV sub-fundEuropean marketArticle 9
Share Class

LU0294249692

A high conviction, sustainable European equity strategy
  • Rigorous stock screening combined with bottom-up fundamental analysis form the bedrock of the investment process.
  • On the lookout for long-term growth, built on robust fundamentals and strong business models.
  • A socially responsible Fund that aims to positively contribute to the environment and society.
Key documents
Asset Allocation
Equities95.2 %
Other4.8 %
Data as of:  Aug 29, 2025.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 69.8 %
+ 75.5 %
+ 24.8 %
+ 30.4 %
- 7.5 %
From 30/04/2007
To 25/09/2025
Calendar Year Performance 2024
- 2.1 %
+ 4.6 %
+ 9.7 %
- 10.3 %
+ 34.0 %
+ 13.4 %
+ 20.8 %
- 21.7 %
+ 13.9 %
+ 10.4 %
Net Asset Value
169.77 €
Asset Under Management
605 M €
Net Equity Exposure29/08/2025
95.2 %
SFDR - Fund Classification

Article

9
Data as of:  Sep 25, 2025.

Carmignac Portfolio Grande Europe fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  Aug 29, 2025.
Fund management team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager

Market environment

  • August saw fairly solid returns across most major asset classes, with the MSCI Europe up around 1%.
  • Resilient activity data helped returns: the eurozone composite PMI reached a flash 51.1 in August, driven by manufacturing.
  • European politics added further volatility, the French prime minister called a vote of no confidence in his minority government scheduled for 8 September, after he was unable to muster support for budget cuts.

Performance commentary

  • In August, the fund posted negative returns in both absolute and relative terms.
  • Technology was the primary detractor, as several major firms reported earnings that either fell short of expectations or included cautious forward guidance, weighing on sector performance.
  • The Healthcare sector also underperformed relative to our reference indicator with Alcon being the main detractor. The company faced pressure from disappointing revenue figures, revised guidance, and concerns around tariffs.
  • In contrast, Novo Nordisk and Zealand Pharma were standout performers, rebounding strongly after prior weakness. Both companies, which specialize in treatments for weight-related conditions, delivered impressive returns of +15% and +27% respectively in August.
  • The Industrials sector which we reinforced in the recent months was the biggest relative contributor.
  • Prysmian which has been a contributor to the Fund for the past few months continued its strong momentum, capitalizing on robust demand in electrification and digital infrastructure.

Outlook strategy

  • In August, we initiated a new position in Novonesis, a leading producer of food ingredients and enzymes, capitalizing on a meaningful market pullback that presented an attractive entry point.
  • We also trimmed exposure to momentum-driven names, realizing gains in UBS, BBVA, Nordnet, and Prysmian following a period of strong performance.
  • Conversely, we increased our allocation to SPIE, which experienced a sell-off amid political tensions in France. We believe the downside risk is limited, given the company’s primary revenue exposure is in Germany.
  • As investor focus shifts back to the fragility of the global economy and the looming threat of tariffs, sentiment may turn more cautious.
  • In this environment, high-quality companies stand out, supported by robust financials, resilient earnings, and compelling long-term growth prospects.
  • This backdrop creates an attractive entry point for long-term investors, particularly as markets refocus on fundamentals and earnings visibility becomes increasingly valuable.

Performance Overview

Data as of:  Sep 25, 2025.
Source: Carmignac at 28/09/2025

Carmignac Portfolio Grande Europe Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  Aug 29, 2025.
Europe100.0 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  Aug 29, 2025.
Equity Investment Weight95.2 %
Net Equity Exposure95.2 %
Number of Equity Issuers47
Active Share80.6 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Manager.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
In our approach to European equities, we focus on sustainable high-quality companies which demonstrate high levels of profitability while favouring profits reinvestment over profits distribution to grow the business for the future.
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
View Fund's characteristics

Articles that may interest you

European equitiesJuly 14, 2025English

Carmignac Portfolio Grande Europe: Letter from the Fund Manager - Q2 2025

3 minute(s) read
Find out more
European equitiesJuly 8, 2025English

Banking on (non-traditional) financials

5 minute(s) read
Find out more
European equitiesJuly 4, 2025English

Mark Denham named Best Alpha Manager by Fundinfo

1 minute(s) read
Find out more